Shareholders Approve 8x Authorized Share Increase and Reverse Split Authority
LABT is trading near its 52-week low of $1.1 (2.7% below the low) on elevated volume (15× avg).
Summary
Shareholders approved an 8x increase in authorized shares to 100 million and granted the board authority to execute a reverse split up to 1:20, setting the stage for major dilution and potential Nasdaq compliance moves.
Key Events · Corporate Governance and Compliance · LABT
-
Authorized Shares Increased 8x to 100M
Shareholders approved increasing authorized common shares from 12,500,000 to 100,000,000, giving the company massive headroom for future dilution against the current 2,369,688 shares outstanding.
-
Reverse Split Authority Approved
The board was authorized to effect one or more reverse stock splits at a cumulative ratio not exceeding 1:20, likely to regain Nasdaq compliance given the stock trades near its 52-week low of $1.10.
-
Equity Incentive Plan Expanded
The 2020 Equity Incentive Plan was amended to increase shares issuable thereunder to 400,000, adding further potential dilution.
-
Directors Elected and Auditor Ratified
All four director nominees were elected, and CBIZ CPAs P.C. was ratified as the independent registered public accounting firm.
Analysis · LABT · Life Sciences
Lakewood-Amedex shareholders approved an 8x increase in authorized common shares from 12.5 million to 100 million, plus authority for a reverse stock split of up to 1:20. The company is trading near its 52-week low at $1.07 with a market cap of only $2.7 million, and the Q2 10-Q showed a $4.7 million H1 net loss and unremediated material weaknesses. The authorized share increase gives the company massive headroom for future dilution — if all 100 million shares were issued against the current 2.37 million outstanding, dilution would be over 40x. The reverse split authority is likely aimed at regaining Nasdaq compliance, but it also signals the stock price is under severe pressure. The combination of these approvals, against the backdrop of ongoing losses and a terminated placement agency agreement, suggests the company is preparing for significant capital raises that will heavily dilute existing holders.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LABT was trading at $1.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $1.10 to $98.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.